NR2F1 Foundation Appoints First Executive Director to Accelerate Rare Disease Research

NR2F1 Foundation

For seven years, the NR2F1 Foundation ran on volunteer labor and family determination. Parents of children with a rare genetic condition called Bosch-Boonstra-Schaaf Optic Atrophy Syndrome (BBSOAS) built a research advocacy organization from scratch, raised funds, convened scientists, and connected families scattered across the globe. Now they have hired their first paid leader.

What BBSOAS is and why it needs a foundation

Bosch-Boonstra-Schaaf Optic Atrophy Syndrome is caused by mutations in the NR2F1 gene, also known as COUP-TF1. The condition affects visual development, often causing optic atrophy (degeneration of the optic nerve), along with intellectual disability, developmental delays, and sometimes seizures and autism spectrum features. It is rare enough that many physicians have never seen a case, making diagnosis difficult and research funding scarce.

Rare disease foundations face a particular set of challenges. The patient population is small, so pharmaceutical companies have limited financial incentive to develop treatments. Academic researchers may be interested but struggle to find funding through conventional grant mechanisms that favor diseases affecting larger populations. Families often become the primary engine of research progress, raising money and building the infrastructure that connects researchers to patients and biological samples.

From volunteer organization to professional operation

The NR2F1 Foundation was established in 2018. Since then, its work has been driven entirely by families and volunteers. That model carried the organization through its formative years, building a global community, establishing a Scientific Advisory Board, and funding initial research efforts. But as the foundation's ambitions have grown, so has the need for sustained professional leadership.

Leora Westbrook, the new executive director, brings experience in healthcare, nonprofit leadership, and fundraising. Her role will focus on strengthening operations, expanding fundraising and partnerships, raising awareness of BBSOAS, and fostering collaboration among researchers, clinicians, and families.

"This step reflects how far our community has come, and how much more we can achieve together," said Jennifer Coughlin, president of the NR2F1 Foundation.

What professional leadership enables

The transition from volunteer to professional leadership matters for practical reasons. Grant applications require dedicated staff time. Relationships with pharmaceutical companies need consistent points of contact. Natural history studies, which track how a disease progresses in patients over time and are essential for clinical trial design, require sustained coordination across multiple clinical sites. Patient registries need maintenance and growth. All of these activities benefit from someone whose full-time job is making them happen.

For researchers working on NR2F1-related biology, a professionally staffed foundation can serve as a more reliable partner, one that can facilitate patient recruitment, coordinate biological sample collection, and provide the organizational continuity that multi-year research collaborations require.

The rare disease context

The NR2F1 Foundation's trajectory mirrors a pattern common in the rare disease world. Families identify a condition, connect with each other (often through social media), form an advocacy organization, and gradually build the scientific and institutional infrastructure needed to attract research attention. The hire of a first executive director typically signals that an organization has reached a level of maturity and fundraising capacity that justifies the investment.

Whether this translates into faster research progress depends on many factors beyond the foundation's control, including the basic biology of the NR2F1 gene, the tractability of potential therapeutic targets, and the willingness of researchers and companies to invest time and resources in a very small patient population.

Honest constraints

A single executive director hire does not transform a small rare disease foundation into a large research organization overnight. The BBSOAS patient population remains small, limiting the scale of clinical studies that can be conducted. Funding for rare diseases continues to be challenging, and competition for philanthropic and grant dollars is intense across the rare disease space. The timeline from foundational research to potential treatments is measured in years to decades, not months.

The announcement is a milestone in organizational development, not a scientific breakthrough. Its significance lies in building the capacity that could eventually support meaningful research progress, rather than in any immediate change in treatment options for patients.